CLNN लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 23:35):

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics...

Stats
आज की मात्रा	186 618
औसत मात्रा	891 846
बाजार मूल्य	46.85M
EPS	$0 ( 2024-05-10 )
अगली कमाई की तारीख	( $-0.0800 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.780
ATR14	$0.00400 (1.07%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	General Resonance Llc	Sell	13 000	Common Stock
2024-05-01	General Resonance Llc	Sell	13 000	Common Stock
2024-04-24	General Resonance Llc	Sell	10 000	Common Stock
2024-04-09	General Resonance Llc	Sell	7 500	Common Stock
2024-04-09	General Resonance Llc	Sell	7 500	Common Stock

INSIDER POWER
98.96
Last 99 transactions
Buy: 46 123 962 \| Sell: 192 230

मात्रा सहसंबंध

लंबा: -0.20 (neutral)

छोटा: -0.15 (neutral)

Signal:(53.578) Neutral

Clene Inc. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Clene Inc. सहसंबंध - मुद्रा/वस्त्र

0.55
( weak )

0.53
( weak )

0.00
( neutral )

-0.50
( weak negative )

Clene Inc. वित्तीय

Annual	2023
राजस्व:	$654 000
सकल लाभ:	$-1.17M (-179.20 %)
EPS:	$-0.470

FY	2023
राजस्व:	$654 000
सकल लाभ:	$-1.17M (-179.20 %)
EPS:	$-0.470

FY	2022
राजस्व:	$473 000
सकल लाभ:	$447 000 (94.50 %)
EPS:	$-0.230

FY	2021
राजस्व:	$723 000
सकल लाभ:	$434 000 (60.03 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Clene Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.